Analgesic effect of ropivacaine combined with methylene blue in fascia Iliaca block for patients undergoing hip arthroplasty

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

The duration of a single fascia iliaca compartment block (FICB) with ropivacaine is limited.

This study investigated whether methylene blue as an adjuvant anesthetic in FICB can enhance the postoperative analgesic effect following total hip arthroplasty (THA).

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Patients who planned to undergo THA were recruited for this randomized clinical trial from June 2023 to February 2024.

Ninety elderly patients undergoing THA were randomly divided into two groups that received ultrasound-guided FICB with either ropivacaine and methylene blue (MB + R group, n = 45) or ropivacaine only (R group, n = 45) before induction of general anesthesia.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

The primary outcomes were postoperative Visual Analog Scale (VAS) scores.

Secondary outcomes included inflammatory factor levels, heart rate (HR), mean arterial pressure (MAP), postoperative analgesic use, postoperative activity, and adverse events.

What Was Measured

The subject headings attached to it are Ropivacaine, Arthroplasty, Replacement, Hip, Methylene Blue, Postoperative Pain, Nerve Block, Anesthetics, Local and Pain Measurement.

The authors tagged it with the keywords Analgesia, Fascia Iliaca compartment block and Total hip arthroplasty.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (BMC musculoskeletal disorders), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.